The estimated Net Worth of John M. Evans is at least $47.9 millió dollars as of 27 June 2024. Mr. Evans owns over 60,000 units of Beam Therapeutics stock worth over $24,080,033 and over the last 4 years he sold BEAM stock worth over $21,566,385. In addition, he makes $2,209,800 as Chief Executive Officer és Director at Beam Therapeutics.
John has made over 16 trades of the Beam Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 60,000 units of BEAM stock worth $1,470,000 on 27 June 2024.
The largest trade he's ever made was exercising 115,000 units of Beam Therapeutics stock on 16 April 2020 worth over $118,450. On average, John trades about 33,911 units every 81 days since 2020. As of 27 June 2024 he still owns at least 998,343 units of Beam Therapeutics stock.
You can see the complete history of Mr. Evans stock trades at the bottom of the page.
John M. Evans serves as Chief Executive Officer, Director of the Company. Mr. Evans has significant experience as a company builder, dealmaker, and drug developer in the biotechnology industry. Mr. Evans has also served as a Venture Partner with ARCH Venture Partners since 2017 and as a Director of Verve Therapeutics since August 2018. Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals, from September 2009 until April 2017, most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. At Agios, Mr. Evans served as IDH Portfolio Executive, providing strategic and operational leadership for a portfolio of first-in-class IDH inhibitors including IDHIFA and TIBSOVO. He helped initiate and lead Agios’ landmark alliance with Celgene, resulting in over $600 million of funding and investments across multiple research collaborations in cancer metabolism. At Agios, Mr. Evans led a team of eight employees. He also co-led Agio’s expansion into rare genetic diseases. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals, McKinsey & Company’s pharmaceuticals practice and MedImmune. Mr. Evans holds an MBA in Healthcare Management from Wharton, a M.S. in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.
As the Chief Executive Officer és Director of Beam Therapeutics, the total compensation of John Evans at Beam Therapeutics is $2,209,800. There are 1 executives at Beam Therapeutics getting paid more, with Terry-Ann Burrell having the highest compensation of $4,302,720.
John Evans is 42, he's been the Chief Executive Officer és Director of Beam Therapeutics since 2020. There are 14 older and 1 younger executives at Beam Therapeutics. The oldest executive at Beam Therapeutics Inc. is Mark Fishman, 68, who is the Independent Director.
John's mailing address filed with the SEC is C/O BEAM THERAPEUTICS INC.,, 238 MAIN STREET, CAMBRIDGE, MA, 02142.
Over the last 5 years, insiders at Beam Therapeutics have traded over $63,012,019 worth of Beam Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Llc Fmr és Kristina Burow. On average, Beam Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $1,019,987. The most recent stock trade was executed by Amy Simon on 1 July 2024, trading 1,250 units of BEAM stock currently worth $29,100.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Beam Therapeutics executives and other stock owners filed with the SEC include: